Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Evaluation of the use of therapeutic peptides for cancer treatment.

Marqus S, Pirogova E, Piva TJ.

J Biomed Sci. 2017 Mar 21;24(1):21. doi: 10.1186/s12929-017-0328-x. Review.

2.

Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells.

Zhang J, Su L, Ye Q, Zhang S, Kung H, Jiang F, Jiang G, Miao J, Zhao B.

Oncotarget. 2017 Jan 31;8(5):7625-7636. doi: 10.18632/oncotarget.13825.

3.

MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.

Sadeghi M, Ranjbar B, Ganjalikhany MR, M Khan F, Schmitz U, Wolkenhauer O, Gupta SK.

PLoS One. 2016 Dec 22;11(12):e0168760. doi: 10.1371/journal.pone.0168760. eCollection 2016.

4.

Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.

Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers CL, Elashoff D, Horvath S, Huang J, Witte ON, Goldstein AS.

Cell Rep. 2016 Dec 6;17(10):2596-2606. doi: 10.1016/j.celrep.2016.11.010.

5.

Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer.

Lee JH, Kim C, Baek SH, Ko JH, Lee SG, Yang WM, Um JY, Sethi G, Ahn KS.

Oncotarget. 2017 Mar 14;8(11):17700-17711. doi: 10.18632/oncotarget.10775.

6.

The Modulation of Apoptotic Pathways by Gammaherpesviruses.

Banerjee S, Uppal T, Strahan R, Dabral P, Verma SC.

Front Microbiol. 2016 Apr 27;7:585. doi: 10.3389/fmicb.2016.00585. eCollection 2016. Review.

7.

Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies.

Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D'Orazi G.

Aging (Albany NY). 2016 Apr;8(4):603-19. doi: 10.18632/aging.100934. Review.

8.

4C-seq revealed long-range interactions of a functional enhancer at the 8q24 prostate cancer risk locus.

Cai M, Kim S, Wang K, Farnham PJ, Coetzee GA, Lu W.

Sci Rep. 2016 Mar 3;6:22462. doi: 10.1038/srep22462.

9.

Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy.

Neo SH, Lew QJ, Koh SM, Zheng L, Bi X, Chao SH.

Oncotarget. 2016 Feb 2;7(5):5483-94. doi: 10.18632/oncotarget.6794.

10.

A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.

Stein MN, Hussain M, Stadler WM, Liu G, Tereshchenko IV, Goodin S, Jeyamohan C, Kaufman HL, Mehnert J, DiPaola RS.

Clin Genitourin Cancer. 2016 Feb;14(1):22-7. doi: 10.1016/j.clgc.2015.09.010. Epub 2015 Sep 21.

11.

Treatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer Agents.

Modica-Napolitano JS, Weissig V.

Int J Mol Sci. 2015 Jul 29;16(8):17394-421. doi: 10.3390/ijms160817394. Review.

12.

Novel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer Cells.

Ingersoll MA, Lyons AS, Muniyan S, D'Cunha N, Robinson T, Hoelting K, Dwyer JG, Bu XR, Batra SK, Lin MF.

PLoS One. 2015 Jun 29;10(6):e0131811. doi: 10.1371/journal.pone.0131811. eCollection 2015.

13.

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.

Greasley R, Khabazhaitajer M, Rosario DJ.

Cancer Manag Res. 2015 Jun 12;7:153-64. doi: 10.2147/CMAR.S50585. eCollection 2015. Review.

14.

Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.

Lin HP, Lin CY, Huo C, Hsiao PH, Su LC, Jiang SS, Chan TM, Chang CH, Chen LT, Kung HJ, Wang HD, Chuu CP.

Oncotarget. 2015 Mar 30;6(9):6684-707.

15.

TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival.

Raphaël M, Lehen'kyi V, Vandenberghe M, Beck B, Khalimonchyk S, Vanden Abeele F, Farsetti L, Germain E, Bokhobza A, Mihalache A, Gosset P, Romanin C, Clézardin P, Skryma R, Prevarskaya N.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):E3870-9. doi: 10.1073/pnas.1413409111. Epub 2014 Aug 29.

16.

Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells.

Muniyan S, Chou YW, Ingersoll MA, Devine A, Morris M, Odero-Marah VA, Khan SA, Chaney WG, Bu XR, Lin MF.

Cancer Lett. 2014 Oct 10;353(1):59-67. doi: 10.1016/j.canlet.2014.07.002. Epub 2014 Jul 19.

17.

Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).

Pillai RN, Aisner J, Dahlberg SE, Rogers JS, DiPaola RS, Aisner S, Ramalingam SS, Schiller JH.

Cancer Chemother Pharmacol. 2014 Jul;74(1):177-83. doi: 10.1007/s00280-014-2427-7. Epub 2014 May 24.

18.

Marine- and plant-derived ω-3 fatty acids differentially regulate prostate cancer cell proliferation.

Eser PO, Vanden Heuvel JP, Araujo J, Thompson JT.

Mol Clin Oncol. 2013 May;1(3):444-452. Epub 2013 Feb 15.

19.

Subditine, a new monoterpenoid indole alkaloid from bark of Nauclea subdita (Korth.) Steud. induces apoptosis in human prostate cancer cells.

Liew SY, Looi CY, Paydar M, Cheah FK, Leong KH, Wong WF, Mustafa MR, Litaudon M, Awang K.

PLoS One. 2014 Feb 14;9(2):e87286. doi: 10.1371/journal.pone.0087286. eCollection 2014.

20.

Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.

Lin HP, Lin CY, Hsiao PH, Wang HD, Jiang SS, Hsu JM, Jim WT, Chen M, Kung HJ, Chuu CP.

PLoS One. 2013 Dec 5;8(12):e82625. doi: 10.1371/journal.pone.0082625. eCollection 2013.

Supplemental Content

Support Center